June 28, 2021
The Pharmaceuticals and Medical Devices Agency (PMDA) is investigating new side effect risks for 14 APIs including Astellas Pharma’s osteoporosis treatment Evenity (romosozumab), a move likely to trigger label changes in the near future. According to the agency’s risk communication...read more